Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
30 Juin 2021 - 3:08AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing curative therapeutics
using CRISPR/Cas9 technology both in vivo and ex
vivo, announced today the pricing of an underwritten public
offering of 4,137,931 shares of its common stock at a public
offering price of $145.00 per share. Intellia also granted the
underwriters a 30-day option to purchase up to an additional
620,689 shares of its common stock. The gross proceeds from the
offering, before deducting underwriting discounts and commissions
and offering expenses, are expected to be approximately $600
million, excluding any exercise of the underwriters' option to
purchase additional shares. All of the shares in the offering are
to be sold by Intellia.
Goldman Sachs & Co. LLC, Jefferies, SVB Leerink, and
Barclays are acting as joint book-running managers for the
offering. Truist Securities is acting as co-manager for the
offering. The offering is expected to close on or about July 2,
2021, subject to customary closing conditions.
The shares of common stock are being offered by Intellia
pursuant to an effective shelf registration statement that was
previously filed with the U.S. Securities and Exchange Commission
(SEC). A preliminary prospectus supplement and accompanying
prospectus relating to and describing the terms of the offering was
filed with the SEC on June 28, 2021. The final prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and may be obtained, when available,
from: Goldman Sachs & Co. LLC, by mail at 200 West Street, New
York, NY 10282, Attention: Prospectus Department, by telephone at
(866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or
Jefferies LLC, by mail at 520 Madison Avenue, 2nd Floor, New York,
NY 10022, Attention: Equity Syndicate Prospectus Department, by
telephone at (877) 547-6340, or by email at
Prospectus_Department@Jefferies.com; SVB Leerink LLC, by mail at
One Federal Street, 37th Floor, Boston, MA 02110, Attention:
Syndicate Department, by telephone at (800) 808-7525, ext. 6105, or
by email at syndicate@svbleerink.com; or Barclays Capital Inc., by
mail at c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by
email at barclaysprospectus@broadridge.com; or by accessing the
SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
using CRISPR/Cas9 technology.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Intellia’s anticipated public offering. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, such as the
intended offering terms, are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in Intellia’s most recent annual report on
Form 10-K and quarterly report on Form 10-Q filed with the SEC, as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the SEC,
including those contained or incorporated by reference in the
preliminary prospectus supplement and accompanying prospectus
related to the public offering filed with the SEC. Any
forward-looking statements contained in this press release
represent Intellia’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date. Intellia explicitly disclaims any obligation to update any
forward-looking statements, except as required by law.
Intellia Contacts:
Investors:Lina LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communications+1-917-640-7930media@intelliatx.commcrenson@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024